Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children

Overview

The objectives of this study are: 1. To see if autologous human umbilical cord blood treatment is safe for children with acquired hearing loss, and 2. To determine if late functional outcome is improved following autologous human umbilical cord blood treatment for children with acquired hearing loss.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2013

Detailed Description

Acquired sensorineural hearing loss is characterized by a loss of functioning hair cells in the Organ of Corti, with greater hair cell loss correlating with more severe hearing impairment. Children with sensorineural hearing loss experience difficulty developing normal language which usually leads to poor academic and social development. Currently, there are no reparative therapeutic options available, and treatments are designed to augment the diminished function of the injured Organ of Corti. Pre-clinical data suggest progenitor cell infusions may enhance intrinsic repair mechanisms in the Organ of Corti which may restore hair cells. This treatment could ultimately lead to hearing improvement. Human umbilical cord blood (hUCB) is an available, autologous, stored progenitor cell population available for potential therapeutic use. The primary objective of this study is to determine the safety of autologous hUCB infusion in children with acquired hearing loss. The secondary objective is to determine if functional, physiologic and anatomic outcomes are improved following hUCB treatment in this patient population.

Interventions

  • Biological: Autologous Human Umbilical Cord Blood
    • 6 million cells/kg will be administered intravenously at one treatment time point.

Arms, Groups and Cohorts

  • Experimental: Biologic; Autologous Cell Injection

Clinical Trial Outcome Measures

Primary Measures

  • Physiologic Outcome
    • Time Frame: One year
    • Age appropriate physiologic outcome measures will be recorded pre-treatment, and one year following hUCB treatment

Secondary Measures

  • Functional Outcome
    • Time Frame: one year
    • Age appropriate Speech-Language assessments will be performed pre-treatment and one year post-treatment.

Participating in This Clinical Trial

Inclusion Criteria

1. Evidence of a moderate to profound sensorineural hearing loss. 2. Normally shaped cochlea, as determined by MRI. 3. The loss must be considered acquired, NOT syndromic. 4. The patient must be fitted for hearing aids of the detection of the loss. 5. Enrollment in a parent/child intervention program. 6. Between 6 weeks and 18 months of age at the time of cord blood infusion. 7. Ability of child and caregiver to travel to Houston for treatment and all follow-up appointments. (Patient's family is responsible for the cost of travel to and lodging in Houston). Exclusion Criteria:

1. Inability to obtain pertinent medical records. 2. Known history or

  • Recently treated ear or other infection. – Renal disease. – Hepatic disease. – Malignancy. – HIV. – Immunosuppression (WBC < 3,000). – Evidence of an extensive stroke (> 100ml). – Pneumonia, or chronic lung disease. 3. hUCB sample contamination. 4. Participation in a concurrent intervention study. 5. Desire for organ donation in the event of death. 6. Unwillingness or inability to stay 4 days following hUCB infusion, and to return for the one month, six month and one year follow-up visits. 7. Presence of a cochlear implant device. 8. Evidence of a syndrome. 9. Positive test for genetic hearing loss. 10. Evidence of conductive hearing loss. 11. Documented evidence of recurrent middle ear infections (> 5/year). 12. Otitis media at the time of examination. 13. Mild sensorineural hearing loss. 14. Over 18 months at the time of infusion.

Gender Eligibility: All

Minimum Age: 6 Weeks

Maximum Age: 18 Months

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Aryn Knight
  • Collaborator
    • Cord Blood Registry, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Aryn Knight, AVP Research – Memorial Hermann Health System
  • Overall Official(s)
    • James E. Baumgartner, MD, Principal Investigator, MHHS, Houston,TX & FL Hospital for Children, Orlando, FL
    • Linda S. Baumgartner, CCC-SLP, LSLS CERT.AVT, Principal Investigator, Speech Therapists for Children
    • Samir Fakhri, MD, Principal Investigator, The University of Texas Health Science Center, Houston

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.